At its Meeting on 23 May 2022, the Transparency Council adopted Position No. 48/2022 on the evaluation of Xtandi (enzalutamidum) under the drug programme “Treatment of hormone-sensitive metastatic prostate cancer (ICD-10 C61)”.
At its Meeting on 23 May 2022, the Transparency Council adopted Position No. 48/2022 on the evaluation of Xtandi (enzalutamidum) under the drug programme “Treatment of hormone-sensitive metastatic prostate cancer (ICD-10 C61)”.